Background. The relationship between vitamin D (vit-D) levels and the effectiveness of infliximab (IFX) in patients with Crohn’s disease (CD) remains controversial. Objective. To evaluate the interaction between vit-D levels and the response to IFX therapy in patients with CD. Methods. This was a retrospective cohort study. Serum vit-D and IFX trough concentrations (TC) were measured in 84 patients, and statistical analyses were performed. Results. The total vit-D deficiency rate at enrollment, at week 14 and week 38, was 64.3%, 41.67%, and 37.5%, respectively ( ). CD activity index (CDAI) (120, range, 93–142.75) and simplified endoscopic activity score for CD (SES-CD) (2, range, 0–4) at week 14 were lower than that of enrollment (CDAI, 136.5, range, 101.25–196; SES-CD 13, range, 5–23) ( ). The biochemical remission (BR), clinical remission (CR), endoscopic remission (ER), and response (ERe) rates of week 38 were 76.1%, 88.5%, 22.4%, and 67.2%, respectively. vit-D levels at enrollment were positively correlated with CDAI at week 38 ( ). IFX serum TC was related to BR ( ), CR ( ) at week 14, and ERe ( ) at week 38. Conclusion. Among Chinese patients with CD, vit-D levels prior to IFX therapy are related to CDAI scores, and IFX serum TC is associated with BR, CR, and ERe.
5 December 2025 in Journal of Medical Internet Research
Background: The prevalence of inflammatory bowel disease (IBD) has been on the rise, with adolescents and young adults experiencing the highest incidence rates. For these young patients, self-management behaviors are critical to maintaining disease remission and improving quality of life and yet their current self-management status remains suboptimal. Objective: This study aimed to evaluate the impact of a remote and multicomponent intervention program (integrating health education, solution-focused intervention, peer support, and mindfulness training) on the self-management behaviors and related mental health outcomes in young adults and adolescents with IBD. Methods: From July 2024 to January 2025, we conducted a 2-arm, single-blind randomized controlled trial. Adolescents and young adults with IBD (aged 13-24 years) were recruited from gastroenterology wards of 2 tertiary hospitals in Chongqing, China, and randomized 1:1 to the intervention (extra multicomponent program) or control (routine care) group. Outcomes (self-management behaviors, perceived social support, basic psychological needs, anxiety, depression, and disease activity) were assessed postintervention (T1) and 12 weeks later (T2). Intention-to-treat analysis was used: normally distributed data via mixed-design analysis of variance, and nonnormal data via rank sum and Friedman tests. Results: A total of 74 participants (mean age 18.95, SD 2.96 years; 53/74, 72% males) were enrolled (37 per group) with no baseline differences. Compared with the control group, the intervention group showed significantly higher self-management scores at both T1 (mean difference –16.676, 95% CI –24.370 to –8.982; P<.001, η2=0.206) and T2 (mean difference –14.189, 95% CI –22.594 to –5.784; P=.001, η2=0.136), along with higher perceived social support scores at T1 (mean difference –9.000, 95% CI –13.932 to –4.068; P=.001, η2=0.155) and T2 (mean difference –6.649, 95% CI –11.890 to –1.407; P=.01, η2=0.082). Basic psychological needs scores were also higher in the intervention group at T1 (mean difference –4.946, 95% CI –8.323 to –1.569; P=.005, η2=0.106) and T2 (mean difference –3.946, 95% CI –7.720 to –0.172; P=.04, η2=0.057), while anxiety (T1: P=.04; T2: P=.007) and depression (T1: P=.048; T2: P=.03) scores were lower. In addition, the intervention group had a higher disease activity remission rate at T2 (P=.03). Conclusions: This study extended the application of self-determination theory to adolescents and young adults with IBD, offering a novel theoretical basis for self-management practice in this population. It was shown that this multicomponent intervention was a valuable addition to standard care in enhancing self-management behaviors and related mental health outcomes while lowering disease activity. In addition, its alignment of intrinsic behavioral motivation with nurse-driven clinical settings boosted clinical operability of the intervention. Trial Registration: Chinese Clinical Trial Registry ChiCTR2400086703; https://www.chictr.org.cn/showproj.html?proj=235313
4 October 2024 in Clinical and Experimental Medicine
The aim was to evaluate predictors of clinical outcomes in infliximab (IFX)-treated Crohn’s disease (CD) patients in western China and provide evidence for future treatment optimization. Our retrospective study included CD patients at Chongqing General Hospital from July 2022 to July 2023. Clinical data of CD patients at baseline and the endpoint (the seventh IFX treatment, 38 weeks) were collected. Baseline variables of IFX-treated patients with regard to clinical remission [Crohn's Disease Activity Index (CDAI) < 150] at endpoint were assessed, and the correlation of serum vitamin D (Vit-D) levels before initiating IFX therapy and CDAI at week 38 was analyzed. Sixty patients with IFX-treated CD were included. The Vit-D-deficient rate was 51.7% at baseline, 81.7% of patients achieved clinical remission, and 66.7% achieved endoscopic remission at week 38 of IFX treatment. Vit-D level at baseline was an independent predictors of clinical remission after IFX treatment (P < 0.05). Receiver operating characteristic curve analysis showed that when Vit-D concentration was 15.81 ng/ml, the area under the curve was 0.711 (95% CI 0.523–0.899, P = 0.03). The sensitivity and specificity were 81.6% and 63.6%, respectively. Vit-D level in the normal BMI, non-smoking, immunosuppressant-treated subgroup had independent predictive value for CDAI at endpoint (P < 0.05). Baseline Vit-D level predicted clinical remission in CD patients after IFX treatment, especially in those with normal body mass index, who do not smoke, and who take IFX in combination with immunosuppressants.
Background and Aims: Research on the effect of the coronavirus disease 2019 (COVID-19) pandemic on psychosocial function in patients with pediatric-onset inflammatory bowel disease (PIBD) is limited. This study aimed to evaluate the psychological status of patients with PIBD before and during the pandemic, and the relationship between mental health and disease activity.Methods: This study was a retrospective cohort study. Statistical analyses were performed to assess the relationship between demographic, clinical data and psychological data (questionnaires) of PIBD patients before and during the epidemic. The anxiety and depression emotional status of the guardians during the pandemic were evaluated.Results: In the PIBD follow-up cohort, 42 patients(male 61.9%) were included. Female with PIBD had lower pediatric quality of life inventory(PedsQL) scores (P = 0.007) and higher spence children's anxiety scale(SCAS) scores (P = 0.038) than male. The pandemic did not have a substantial impact on PedsQL, pittsburgh sleep quality index(PSQI), SCAS, or children's depression inventory(CDI) in patients with PIBD. The self-rating anxiety scale(SAS) score, anxiety rate, self-rating depression scale(SDS) score, and depression rate of PIBD guardians were significantly higher than those of healthy controls (SAS, P = 0.008; SDS, P = 0.001).Conclusions: Female children with PIBD were more vulnerable to decreased QOL and increased anxiety than male children. The anxiety and depression status of PIBD guardians were significantly higher than those of healthy controls during the COVID-19 pandemic. But the COVID-19 pandemic did not significantly affect quality of life(QOL), sleep, anxiety, or depressive mood of patients with PIBD in our study.
Off‐label use of biologic therapies in patients with pediatric inflammatory bowel disease (IBD) has seen an increase in utilization. In this paper, we review the current state of off‐label therapies in the pediatric IBD population. Real‐world use of ustekinumab (UST), vedolizumab (VDZ), upadacitinib (UPA), tofacitinib, and ozanimod in the adult population could prove positive outcomes in the pediatric population. Established off‐label therapies inch closer to comparable safety, efficacy, and outcomes in pediatric IBD use. Outcomes and use of newer biologic therapies in patients with pediatric IBD have improved with increased rates of steroid‐free clinical remission (SFCR). Novel therapies, including Janus kinase (JAK) inhibitors and sphingosine‐1‐phosphate receptor (S1Pr) modulators, require further studies but could also prove effective.
Therapeutic drug monitoring (TDM) plays an important role in guiding treatment plan adjustments and clinical outcomes in Crohn's disease. To evaluate the role of TDM‐guided optimization of infliximab dosage in patients with pediatric Crohn's disease. Medical records of patients with pediatric Crohn's disease who were treated with infliximab and had proactive TDM from June 2020 to June 2022 at the Children's Hospital of Chongqing Medical University were included. Baseline influencing factors for infliximab trough concentration (TC) and clinical outcomes before and after the treatment change were analyzed to assess the value of adjusting treatment in the patients. Forty‐six patients (male‐to‐female ratio = 1.55:1, age <18 years) were included. Univariate and multivariate analyses showed that hormone exposure (odds ratio: 0.042, 95% confidence interval: 0.002–0.924, p = 0.044), perianal lesions (5.813, 0.984–34.349, p = 0.052), simplified endoscopic score for Crohn's disease (1.656, 1.065–2.577, p = 0.025), and total protein (TP) (0.851, 0.749–0.967, p = 0.014) were correlated with infliximab TC. Shortening the treatment interval increased the infliximab TC (pre vs. post = 1.69 ± 0.8 vs. 12.03 ± 6.64, p = 0.001, n = 12) after 93.9 ± 37.47 days, decreased the pediatric Crohn's disease activity index and simplified endoscopic score for Crohn's disease, and increased the biochemical remission, clinical remission, endoscopic remission, and endoscopic response rates; however, there was no statistical significance. Hormone exposure, perianal lesions, simplified endoscopic score for Crohn's disease, and TP levels before the first infliximab use affected the infliximab TC. Shortening the treatment interval can improve infliximab TC levels and clinical outcomes.